NCT00387270View on ClinicalTrials.gov

Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions

Huntington's Disease

Interventions

DRUG

Dimebon

Dimebon 10 or 20 mg TID x 7 days

Trial Locations (1)

14620

Huntington Study Group, Rochester

Sponsors

Lead Sponsor

Medivation, Inc.

All Listed Sponsors

collaborator

Huntington Study Group

NETWORK

lead

Medivation, Inc.

INDUSTRY